MX2022016367A - Methods and compositions for treating chemotherapy-induced diarrhea. - Google Patents

Methods and compositions for treating chemotherapy-induced diarrhea.

Info

Publication number
MX2022016367A
MX2022016367A MX2022016367A MX2022016367A MX2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A
Authority
MX
Mexico
Prior art keywords
diarrhea
methods
compositions
induced diarrhea
treating chemotherapy
Prior art date
Application number
MX2022016367A
Other languages
Spanish (es)
Inventor
Lisa A Conte
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of MX2022016367A publication Critical patent/MX2022016367A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
MX2022016367A 2020-06-19 2020-06-19 Methods and compositions for treating chemotherapy-induced diarrhea. MX2022016367A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/038691 WO2021257089A1 (en) 2020-06-19 2020-06-19 Methods and compositions for treating chemotherapy-induced diarrhea

Publications (1)

Publication Number Publication Date
MX2022016367A true MX2022016367A (en) 2023-01-30

Family

ID=79268234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016367A MX2022016367A (en) 2020-06-19 2020-06-19 Methods and compositions for treating chemotherapy-induced diarrhea.

Country Status (10)

Country Link
EP (1) EP4168027A4 (en)
JP (1) JP2023538186A (en)
KR (1) KR20230027226A (en)
AU (1) AU2020454132A1 (en)
BR (1) BR112022025741A2 (en)
CA (1) CA3182864A1 (en)
IL (1) IL299028A (en)
JO (1) JOP20220339A1 (en)
MX (1) MX2022016367A (en)
WO (1) WO2021257089A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089592B (en) * 2022-05-21 2024-02-27 复旦大学 Application of multiple tyrosine kinase in preparation of medicines for inhibiting enterovirus 71 type neurotropic viruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202876A1 (en) * 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
DK2632550T3 (en) * 2010-10-31 2017-08-07 Napo Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRIA
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
KR20170103834A (en) * 2015-01-09 2017-09-13 재규어 애니멀 헬스 How to treat diarrhea in companion animals
CN110267663A (en) * 2016-12-06 2019-09-20 卡莱多生物科技有限公司 Chitosan polymer and its correlation technique

Also Published As

Publication number Publication date
WO2021257089A1 (en) 2021-12-23
EP4168027A1 (en) 2023-04-26
IL299028A (en) 2023-02-01
EP4168027A4 (en) 2024-04-03
AU2020454132A1 (en) 2023-02-02
JP2023538186A (en) 2023-09-07
KR20230027226A (en) 2023-02-27
JOP20220339A1 (en) 2023-01-30
BR112022025741A2 (en) 2023-01-03
CA3182864A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MX348184B (en) Methods and compositions for treating hiv-associated diarrhea.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
MX2023004156A (en) Combination therapy for treating cancer.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
CR20220374A (en) Methods of treating splenomegaly
DK1677806T3 (en) Compositions for the treatment of acute and congestion-induced sprains and stretching using hyaluronic acid
JOP20220339A1 (en) Methods and compositions for treating chemotherapy-induced diarrhea
CR20210514A (en) Use of reboxetine to treat narcolepsy
JOP20190276A1 (en) Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
MX2020008881A (en) Methods of treatment of cancer comprising chk1 inhibitors.
MX2022011725A (en) Methods of treating pulmonary injury with cgrp inhibitors.
MX2023006704A (en) Dsg2 compositions and methods for the treatment of covid-19.
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
CA3156680A1 (en) Methods and compositions for treatment of rett syndrome
MX2022012001A (en) Preventative treatment of migraine.
EA202000298A1 (en) ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT
CL2022003634A1 (en) Methods and compositions for the treatment of diarrhea induced by chemotherapy.
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
BR112022001814A2 (en) Multifocal cancer treatment methods
BR112022018315A2 (en) REGIME TO TREAT NEISSERIA GONORRHOEAE INFECTION WITH GEPOTIDACIN
WO2020061067A3 (en) Compositions and methods for treating bone injury
MX2021000207A (en) Dosing regimens for treating hypoxia-associated tissue damage.
MY174065A (en) Methods and compositions for treating hiv-associated diarrhea
Costa et al. Low intensity extracorporeal shockwave therapy on erectile dysfunction—first results from a prospective study